UPCC 05823: Phase 1b/2 trial of Ipilimumab, Nivolumab, and Ciforadenant (adenosine A2a receptor antagonist) in first-line advanced renal cell carcinoma
Enrolling By Invitation
99 years and younger
All
Phase
N/A
1 Location
Brief description of study
To learn if the combination of ciforadenant, ipilimumab, and nivolumab can help to control advanced renal cell carcinoma.
We would like to rely on WCG as the IRB of record for this study.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Updated on
09 Mar 2024.
Study ID: 853835
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
